The project MammoScreen, which we submitted in the context of the call HORIZON-MISS-2021-CANCER-02-01 “Develop new methods and technologies for cancer screening and early detection” has been selected for funding, with the total score of 15/15.
One of the goals of HORIZON-MISS-2021-CANCER-02-01 scheme is to develop and validate new methods and technologies for cancer screening and early detection, preferably non-invasive and more-inclusive than current approaches.
The overall aim of MammoScreen is to generate evidence regarding the use of MammoWave (our recently developed microwave imaging device) as breast cancer (BC) screening technique in population-based programs promoted by national or regional health systems. The clinical trial (multicentric, prospective) will involve thousands of women in at least 10 recruitment centres located in many European countries.
Expected impacts are many, including:
- women will benefit from safe, more inclusive (no age-limitation), more comfortable (no breast compression), accessible and accurate BC screening
- health policy makers will have the evidence to review (and expand) current population-based BC screening programs
UBT Srl has participated in this highly competitive call within a Consortium constituted by:
Toscana Life Sciences Foundation (Italy)
London South Bank University (UK)
ELAROS 24/7 Limited (UK)
Servicio De Salud De Castilla La Mancha (Spain)
Scuola IMT Alti Studi Lucca (Italy)
EVITA – Cancro Hereditário (Portugal)
